New drug approvals in acute myeloid leukemia: what’s the best end point?

Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia

(2015) E. Estey et al.   BLOOD

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

(2015) Xueyan Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

(2015) R B Walter et al.   LEUKEMIA

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

(2014) Lisa Pleyer et al.   ANNALS OF HEMATOLOGY

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

(2014) D. Grimwade et al.   BLOOD

Measureable residual disease (MRD): much ado about nothing?

(2014) R P Gale   BONE MARROW TRANSPLANTATION

Impact of Informative Censoring on the Kaplan-Meier Estimate of Progression-Free Survival in Phase II Clinical Trials

(2014) Federico Campigotto et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

(2013) Sylvain Thépot et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

(2013) A. K. Burnett et al.   BLOOD

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

(2013) S. Nand et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

What does MRD in leukemia really mean?

(2013) J M Goldman et al.   LEUKEMIA

Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry

(2012) L. Pagano et al.   CLINICAL INFECTIOUS DISEASES

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma

(2012) T. M. Herndon et al.   ONCOLOGIST

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

(2011) F. Buccisano et al.   BLOOD

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks

(2010) Loren K. Mell et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

(2010) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia

(2008) Shabbir M.H. Alibhai et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY